18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Dec 13, 2024
Trial Information
Current as of August 31, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging agent called 18F-FAPI-Biotin, which is designed to help doctors see and evaluate different types of cancer more effectively. The researchers want to understand how safe this imaging agent is, how it spreads in the body, and how much radiation it involves compared to other imaging methods. By doing this, they hope to find out if 18F-FAPI-Biotin can provide better information for diagnosing cancers.
To participate in this study, patients should have various solid tumors that have been confirmed by medical testing and must be able to give their consent to join. Unfortunately, pregnant or breastfeeding women and those with serious liver or kidney problems cannot take part. If you decide to join, you will undergo imaging tests using this new agent, and the study will help gather important information on its effectiveness and safety for future cancer care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Various solid tumors with available histopathological findings • Signed informed consent
- Exclusion Criteria:
- • pregnant or lactational women • who suffered from severe hepatic and renal insufficiency
About First Affiliated Hospital Of Fujian Medical University
The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Patients applied
Trial Officials
Weibing Miao, MD
Principal Investigator
First Affiliated Hospital of Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported